Vol 10, No 5 (October 30, 2021): Chinese Clinical Oncology

Review Article on Unresolved Issues in Pancreatic Cancer1

Birth of a solid organ cancer—the cell fusion hypothesis presented with pancreatic cancer as a model: a narrative review
Savio G. Barreto, Nilesh Gardi, Shilpee Dutt
Chinese Clinical Oncology  
2021;
10
(5)
:45
.
A narrative review: has regionalization truly achieved its intended goal in the surgical management of pancreatic cancer?
Alexandra W. Acher, Sharon M. Weber, Timothy M. Pawlik
Chinese Clinical Oncology  
2021;
10
(5)
:46
.
Neoadjuvant therapy in resectable pancreatic cancer—is this the way forward?—a narrative review
Giampaolo Perri, Giovanni Marchegiani, Giuseppe Malleo, Roberto Salvia
Chinese Clinical Oncology  
2021;
10
(5)
:47
.
Do arterial resections improve survival in pancreatic cancer?—a narrative review
Artur Rebelo, Ulrich Ronellenfitsch, Jessica Döbereiner, Jörg Ukkat, Jörg Kleeff
Chinese Clinical Oncology  
2021;
10
(5)
:48
.
Is enhancing recovery after pancreatic cancer surgery even possible?—a narrative review
Monish Karunakaran, Savio George Barreto
Chinese Clinical Oncology  
2021;
10
(5)
:49
.

Review Article on Targeting the DNA Damaging Pathway: PARPi and Beyond2

Integrating PARP inhibitors into the management of breast cancer: where are we?
Hamdy A. Azim, Loay Kassem, Hatem Azim Jr
Chinese Clinical Oncology  
2021;
10
(5)
:50
.

Editorial Commentary on Targeting the DNA Damaging Pathway: PARPi and Beyond2

BReast CAncer gene (BRCA): snapshot of the Middle East
Omalkhair Abulkhair, Nagi S. El Saghir
Chinese Clinical Oncology  
2021;
10
(5)
:51
.

Original Article

Gender-based analysis of pre-residency research productivity among a current United States radiation oncology resident class
Shearwood McClelland III, Blair Murphy, Jerry J. Jaboin, Richard C. Zellars
Chinese Clinical Oncology  
2021;
10
(5)
:52
.

Editorial

Who, how and what of pathology of soft tissue sarcoma
Salvatore Lorenzo Renne
Chinese Clinical Oncology  
2021;
10
(5)
:53
.

Disclosure:

1. The series “Unresolved issues in Pancreatic Cancer” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Dr. Savio George Barreto served as the unpaid Guest Editor for the series.

2. The series “Targeting the DNA Damaging Pathway: PARPi and Beyond” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Dr. Shaheenah Dawood served as the unpaid Guest Editor for the series.